Clinical Trials on Recurrent Gastric Carcinoma

Total 30625 results

SWOG Cancer Research Network
National Cancer Institute (NCI); Eli Lilly and Company; Merck Sharp & Dohme LLC

Recruiting

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
National University Hospital, Singapore

Recruiting

A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma

Singapore
Vanderbilt-Ingram Cancer Center

Withdrawn

Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

Canada
National Cancer Institute (NCI)

Completed

Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer

United States
Asan Medical Center
Korea Health Industry Development Institute

Completed

Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant

Hepatocellular Carcinoma | Hepatocellular Carcinoma Recurrent
Assistance Publique - Hôpitaux de Paris

Recruiting

Certolizumab in Recurrent Implantation Failure (RIF) (CERTIFY)

Recurrent Unexplained Implantation Failure

France
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma

United States
XinWu

Recruiting

Single Arm Phase I Trail of Autologous Tumor Infiltrating Lymphocyte Injection (GT202) in the Treatment of Metastatic or Recurrent Gynecological Tumors

Metastatic or Recurrent Gynecological Tumors

China
Weill Medical College of Cornell University
Oncolys BioPharma Inc

Terminated

Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease

Head and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease

United States
Cancer Hospital of Guangxi Medical University

Recruiting

Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Recruiting

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Recurrent Nasopharyngeal Carcinoma

China
Fujian Cancer Hospital
Zhejiang Cancer Hospital; Sun Yat-sen University; Jiangxi Provincial Cancer Hospital and other collaborators

Unknown

Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma

China
National Cancer Institute (NCI)

Recruiting

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Completed

Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Recurrent Uterine Corpus Sarcoma | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Lung Carcinoid Tumor | Stage IV Renal Cell Cancer | Recurrent Digestive System Neuroendocrine Tumor G1 | Adult Solid Neoplasm | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma and other conditions

Canada
M.D. Anderson Cancer Center

Active, not recruiting

Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

Lung Non-Small Cell Squamous Carcinoma | Stage IIA Lung Cancer AJCC v8 | Neuroendocrine Carcinoma | Lung Atypical Carcinoid Tumor | Minimally Invasive Lung Adenocarcinoma | Lung Neuroendocrine Neoplasm | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Malignant Solid Neoplasm | Rhabdoid Tumor | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Rhabdoid Tumor | Refractory Rhabdoid Tumor | Epithelioid Sarcoma | Kidney Medullary Carcinoma | Atypical Teratoid/Rhabdoid Tumor | Poorly Differentiated Chordoma | Recurrent Atypical... and other conditions

United States, Australia, Canada
Mayo Clinic

Recruiting

A Study of FRaDCs for Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Fallopian Tube Carcinosarcoma | Primary Peritoneal Carcinosarcoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian... and other conditions

United States
SonALAsense, Inc.

Active, not recruiting

A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM

Recurrent GBM

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Breast Carcinoma | Fallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Solid Neoplasm

United States
Klus Pharma Inc.

Completed

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Cervical Cancer | Head and Neck Cancer | Mucoepidermoid Carcinoma | Pancreatic Cancer | Recurrent Prostate Cancer | Lung Cancer | Rectal Cancer | Solid Tumor | Prostate Cancer | Cholangiocarcinoma | Bile Duct Cancer | Recurrent Ovarian Carcinoma | Bladder Cancer | Skin Cancer | HER2-positive Breast Cancer | Rare Diseases | Colo-rectal Cancer and other conditions

United States
University of Southern California
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Recurrent Prostate Cancer | Stage III Renal Cell Cancer | Recurrent Endometrial Carcinoma | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IIIA Breast... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)
AstraZeneca; NRG Oncology

Active, not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian... and other conditions

United States, Canada, Korea, Republic of, Japan
Eye & ENT Hospital of Fudan University
Changhai Hospital; Shanghai Zhongshan Hospital; Fujian Medical University Union... and other collaborators

Not yet recruiting

Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

Recurrent Nasopharyngeal Carcinoma

China
Eye & ENT Hospital of Fudan University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC

Recurrent Nasopharyngeal Carcinoma

China
Eye & ENT Hospital of Fudan University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Shanghai...

Not yet recruiting

Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT

Recurrent Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Recruiting

Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Unknown

A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.

Recurrent Nasopharyngeal Carcinoma

China
Chinese University of Hong Kong

Completed

MK-2206 in Recurrent Nasopharyngeal Carcinoma (MC1079)

Recurrent Nasopharyngeal Carcinoma

Hong Kong
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial Carcinoma | Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Endometrial Mixed Cell Adenocarcinoma | Recurrent Endometrial Serous Adenocarcinoma | Recurrent Endometrial Undifferentiated... and other conditions

United States
Casey Cosgrove

Recruiting

Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma

Recurrent Endometrial Serous Adenocarcinoma

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Head and Neck Squamous Cell Cancer | Recurrent Head and Neck Squamous Cell Cancer | Metastatic Head and Neck Squamous Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Breast Carcinoma | Ovarian Carcinoma | Pancreatic Carcinoma | Prostate Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative... and other conditions

United States
National Cancer Institute (NCI)

Completed

Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Oral Cavity Verrucous Carcinoma | Tongue... and other conditions

United States
National Cancer Institute (NCI)

Completed

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Malignant Solid Neoplasm | Recurrent Thyroid Gland Carcinoma | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Thyroid Gland Medullary Carcinoma

United States, Canada
National Cancer Institute (NCI)

Completed

Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy (MAESTRO HN)

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Salivary Gland Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Nasopharyngeal Keratinizing Squamous... and other conditions

United States, China
National Cancer Institute (NCI)

Completed

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

Lung Carcinoid Tumor | Metastatic Digestive System Neuroendocrine Tumor G1 | Pancreatic Polypeptide Tumor | Multiple Endocrine Neoplasia Type 1 | Pancreatic Glucagonoma | Pancreatic Insulinoma | Somatostatin-Producing Neuroendocrine Tumor | Recurrent Digestive System Neuroendocrine Tumor G1 | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Completed

Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer | Pancreatic Acinar Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Recurrent Platinum-Resistant Ovarian Carcinoma | Metastatic Fallopian Tube Carcinoma | Metastatic Primary... and other conditions

United States
National Cancer Institute (NCI)

Completed

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (S1310)

Hilar Cholangiocarcinoma | Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Recurrent Gallbladder Carcinoma | Stage IV Distal Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Carcinoma | Stage II Gallbladder Cancer | Stage... and other conditions

United States
National Cancer Institute (NCI)

Completed

RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage IV Primary Peritoneal Cancer

United States, Canada
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric Cancer Third Line

Spain, Italy, Australia, Korea, Republic of, Belgium, France, Poland, United States, Czechia, Germany
University of Utah

Withdrawn

Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity (WAR)

Recurrent Ovarian Carcinoma

United States
Asan Medical Center
Hoffmann-La Roche

Completed

Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX

Metastatic or Recurrent Gastric Adenocarcinoma | Her-2 Positive Gastric Cancer

Korea, Republic of
Telix International Pty Ltd
Grand Pharmaceutical (China) Co., Ltd.

Completed

Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma (ZIRDOSE-CP)

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Cancer | Suspected Recurrent Renal Clear Cell Carcinoma

China
Institute For Advanced Reconstruction

Unknown

Review of Complex Recurrent Hernia Repair (BARS)

Recurrent Hernia

United States
University of Washington
National Cancer Institute (NCI)

Terminated

A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer (ADAPT)

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal Cancer

United States
BioNTech SE

Recruiting

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

Recurrent Head and Neck Cancer | Unresectable Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Cancer

Germany, United States, France, United Kingdom, Korea, Republic of, Spain, Poland, Belgium, Brazil, Taiwan, Italy, Canada, Czechia, Australia, Turkey, Mexico, Chile, Argentina, Austria, Hungary, Portugal, Sweden
National Cancer Institute (NCI)
NRG Oncology

Completed

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma | Recurrent Cervical Carcinoma | Stage IVB Cervical Cancer

United States, Spain

Clinical Trials on Recurrent Gastric Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations